Company news: CVS, LiveStrong

Share this article:
CVS is getting serious about generics, and has knocked off a few brand names from its PBM formulary for 2013, reported the Wall Street Journal. The Journal noted that the drugstore chain started eliminating high-cost prescriptions over the summer. Some of these have made their way back onto the formulary, including Lilly/BI's Tradjenta, but the drug store chain is striking Allergan's glaucoma medicine Lumigan, Pfizer's human growth hormone Genotropin and the BMS/AstraZeneca diabetes med Onglyza, reported the WSJ.

Shifting gears faster than some expected, the Livestrong Foundation and Lance Armstrong have parted ways, reported the New York Times. The disgraced cyclist and cancer survivor founded the Livestrong foundation in 1997. Although he resigned as chair, following the United States Anti-Doping Agency's conclusion that Armstrong was guilty of doping while competing for the Tour de France, he was still a member of the board until November 4, reported the Times. He was stripped of his Tour titles and banned from future Olympics sports. Jeff Garvey has replaced him as chairman.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.